Trials / Recruiting
RecruitingNCT07526571
GLOW Study: Effects of Triple Protein in Women
GLOW Study: A Randomized Trial to Evaluate the Effects of Triple Support Protein on Glucose, Lifestyle, and Overall Well-being in Women
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- Female
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This single-site, randomized, blinded, placebo-controlled study will evaluate whether 4 weeks of daily Triple Support Protein powder improves glycemic control and overall well-being in healthy women aged 30-60 years. Participants will undergo baseline testing (DXA, fasting blood, standardized meal test with 2-hour glucose and insulin sampling), complete one acute supervised dose, and then consume a daily supplement for 4 weeks. During the final 14 days, participants will wear a continuous glucose monitor. Outcomes include postprandial glucose AUC, insulin sensitivity, and body composition.
Detailed description
Midlife women experience hormonal changes that can impair metabolic health, sleep, and cognition. Triple plant-based protein powder includes creatine and fiber aimed at glycemic control, muscle support, and satiety. Design: 40 participants randomized (1:1) to Triple Protein Support vs. matched placebo for 4 weeks, with acute and chronic phases, weekly check-ins. Assessments: Baseline and end-of-study DXA and bloods; standardized meal tests with 2-hour glucose/insulin sampling; Analysis: Mixed-model ANOVA for primary and secondary endpoints with α=0.05.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Triple protein support | Plant based protein + creatine + fiber |
| DIETARY_SUPPLEMENT | Placebo | Non-caloric matched placebo |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07526571. Inclusion in this directory is not an endorsement.